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a b s t r a c t 
A robust subclassiﬁcation of luminal breast cancer, the most common molecular subtype of human breast 
cancer, is crucial for therapy decisions. While a part of patients is at higher risk of recurrence and requires
chemo-endocrine treatment, the other part is at lower risk and also poorly responds to chemotherapeutic 
regimens. To approximate the risk of cancer recurrence, clinical guidelines recommend determining his- 
tologic grading and abundance of a cell proliferation marker in tumor specimens. However, this approach 
assigns an intermediate risk to a substantial number of patients and in addition suffers from a high interob-
server variability. Therefore, the aim of our study was to identify a quantitative protein biomarker signature 
to facilitate risk classiﬁcation. Reverse phase protein arrays (RPPA) were used to obtain quantitative expres- 
sion data for 128 breast cancer relevant proteins in a set of hormone receptor-positive tumors ( n = 109).
Proteomic data for the subset of histologic G1 ( n = 14) and G3 ( n = 22) samples were used for biomarker
discovery serving as surrogates of low and high recurrence risk, respectively. A novel biomarker selection 
workﬂow based on combining three different classiﬁcation methods identiﬁed caveolin-1, NDKA, RPS6, and 
Ki-67 as top candidates. NDKA, RPS6, and Ki-67 were expressed at elevated levels in high risk tumors whereas
caveolin-1 was observed as downregulated. The identiﬁed biomarker signature was subsequently analyzed 
using an independent test set (AUC = 0.78). Further evaluation of the identiﬁed biomarker panel by Western 
blot and mRNA proﬁling conﬁrmed the proteomic signature obtained by RPPA. In conclusion, the biomarker 
signature introduced supports RPPA as a tool for cancer biomarker discovery. 
c © 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction 
Breast cancer, the most frequent cancer entity among women, 
s nowadays recognized as a heterogeneous disease in terms of tu- 
or morphology as well as at the molecular level [ 1 –3 ]. Treatment 
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Open access under CC BY-NC-NDresult in different outcomes regarding disease progression and sur- 
vival. Over the last few years, gene expression proﬁling has provided 
insights into molecular mechanisms associated with observed hetero- 
geneous clinical outcome [ 4 ]. The seminal work of Sorlie and Perou 
identiﬁed intrinsic molecular subtypes, termed luminal A, luminal B, 
basal-like, and HER2-enriched, with unique biological and prognostic 
features [ 5 ]. The largest group of breast cancer patients suffers from 
luminal breast cancer with overexpression of hormone receptors as 
molecular hallmark. Luminal breast cancer comprises patients of the 
luminal A subtype with good prognosis whereas patients of the lu- 
minal B subtype are at a higher risk to suffer from recurrence [ 6 ]. 
Treatment of patients in these two groups is fundamentally different, 
with patients at higher recurrence risk requiring chemo-endocrine 
treatment, whereas others do not beneﬁt from chemotherapy. Hence,  license.
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 to avoid over- or under-treatment of patients with luminal breast
cancer, tools allowing a clear-cut distinction of low and high risk are
required. Although different approaches employing gene expression
signatures or protein-based assays were introduced [ 7 –11 ], a robust
assessment of the recurrence risk in luminal breast cancer has re-
mained a challenge. 
To differentiate between low and high risk tumors, proliferation
rate has emerged as a prominent feature, mainly supported by gene
expression proﬁling data [ 4 , 12 ]. This is in line with information pro-
vided by histologic grade which is beside age, tumor size, and lymph
node status a well-established independent prognostic factor, com-
bining information on tumor proliferation and differentiation sta-
tus. The Nottingham grading system is based on a semi-quantitative
evaluation of morphologic tumor characteristics, in detail, tubule or
gland formation, nuclear pleomorphism, and mitotic count, features
which essentially reﬂect tumor proliferation and / or differentiation
[ 13 ]. Based on the resulting score, tumor samples are assigned to three
different categories, either well-differentiated (grade 1 / G1), moder-
ately differentiated (grade 2 / G2) or poorly differentiated (grade 3 /
G3) [ 14 ]. For patients whose tumors were characterized as G1 or G3,
prognostic information is univocal, with a good prognosis for G1 and
a poor prognosis for G3 patients. However, a considerable percentage
of patients are classiﬁed as G2 and in this instance a histologic grading
provides no helpful information for treatment decisions. 
In recent years, reverse phase protein arrays (RPPA) have emerged
as a powerful high-throughput approach for targeted proteomics [ 15 ].
As a major advantage, RPPA allows to assess target protein expression
quantitatively in large sample sets while requiring only a very low
amount of biological sample [ 16 ] making this platform attractive for
the analysis of clinical materials and biomarker discovery [ 17 –19 ]. 
The objective of our study was to identify a robust protein signa-
ture using RPPA as a technical platform for targeted proteomics to
assess the risk of cancer recurrence for breast cancer patients whose
tumors had been diagnosed with histologic G2. Quantitative protein
expression data were generated for 128 breast cancer relevant target
proteins analyzing a set of 109 hormone receptor-positive tumors. A
novel bioinformatics workﬂow combining three different classiﬁca-
tion algorithms was used to analyze RPPA data of histologic G1 and
G3 tumors serving as surrogates of low and high risk breast cancer,
respectively. The RPPA-derived signature was ﬁrst subjected to an
independent evaluation employing Western blot and mRNA proﬁling
essentially conﬁrming ﬁndings made by RPPA. Finally, the biomarker
marker proﬁle was translated into a risk classiﬁcation score named
R2LC suitable to predict the recurrence risk in single samples and val-
idated using an independent test set comprising hormone-receptor
positive tumors. 
2. Materials and methods 
2.1. Patient and sample characteristics 
Tumor specimens (discovery set, n = 109) from patients diagnosed
with primary invasive breast carcinoma were collected at the time of
surgery between 2008 and 2010 at the Department of Gynecology and
Obstetrics / National Center for Tumor Diseases, Heidelberg. None of
the patients had received neoadjuvant therapy. Institutional Review
Board approval was received as ethics vote no. S039 / 2008 and in-
formed consent was obtained from all the patients. Tumor specimens
were processed within 20 min after surgery. Samples were stored
snap frozen at −80 ◦C until further use. Tumor specimens of the test
set ( n = 145) were obtained from the Tissue Bank of the National
Center for Tumor Diseases (Heidelberg). Both sample sets comprised
only tumors with > 70% tumor cells and positive estrogen receptor
status (immunoreactive score ≥3) as assessed by routine immuno-
histochemistry. Additional information on patient characteristics is
summarized in Supplementary Tables S1, S2, and S3. 2.2. Reverse phase protein arrays 
Frozen tumor samples were homogenized using a bead mill
(TissueLyser, Qiagen) and tissue protein extraction reagent (T-PER,
Thermo Scientiﬁc) supplemented with 1 mM EDTA, 5 mM NaF, 2 μM
staurosporine, PhosSTOP Phosphatase Inhibitor Cocktail (Roche Ap-
plied Science), and Complete Mini Protease Inhibitor Cocktail (Roche
Applied Science). Total protein concentration was determined by
bicinchoninic acid assay (Thermo Scientiﬁc). Prior to spotting, tu-
mor lysates were mixed with 4 × SDS sample buffer (10% glycerol,
4% SDS, 10 mM DTT, 125 mM Tris–HCl, pH 6.8) and boiled for 5 min
at 95 ◦C. Tumor lysates (total protein concentration 2 μg / μl) and di-
lution series of tumor sample pools serving as controls were spotted
as technical triplicates and four identical subarrays on nitrocellulose-
coated glass slides (Oncyte Avid, Grace-Biolabs) using a contact spot-
ter (Aushon BioSystems). Slides were blocked with blocking buffer for
ﬂuorescent applications (Rockland Immunochemicals) in TBS (50%,
v / v) containing 5 mM NaF and 1 mM Na 3 VO 4 for 2 h at RT, prior to
incubation with target-speciﬁc primary antibodies at 4 ◦C over night
(Supplementary Table S4). Primary antibodies ( n = 128) were selected
to recognize proteins involved in major cancer signaling pathways
with a special focus on breast cancer biology. Only highly target-
speciﬁc antibodies were used and their validation was carried out
as previously described [ 20 ]. Detection of primary antibodies was
done with Alexa Fluor 680 F(ab ′ )2 fragments of goat anti-mouse IgG
or anti-rabbit IgG in 1:8000 dilution (Life Technologies). In addition,
representative slides were stained for total protein quantiﬁcation us-
ing the protein dye Fast Green FCF as described before [ 21 ]. Images
of all slides were obtained at an excitation wavelength of 685 nm
and a resolution of 21 μm using the Odyssey Scanner (LI-COR). Signal
intensities of each individual spot were quantiﬁed using GenePixPro
5.0 (Molecular Devices). Data preprocessing and quality control were
performed with the R-package RPPanalyzer [ 22 ]. RPPA data of the
discovery and the test cohort have been deposited in NCBI ’ s Gene
Expression Omnibus [ 23 ] and are accessible through GEO series ac-
cession number GSE47066 and GSE50861 , respectively. 
2.3. Biomarker selection process bootfs 
We set up a biomarker (feature) selection workﬂow including
three different algorithms for classiﬁcation (SCAD-SVM: support vec-
tor machines using smoothly clipped absolute deviation penalty; RF-
Boruta: random forests using the Boruta algorithm for feature se-
lection; PAM: prediction analysis for microarrays utilizing the near-
est shrunken centroid classiﬁer [ 24 –26 ]). We implemented the soft-
ware in the R programming language and made it available through
the bootfs R-package ( https: // r-forge.r-project.org / projects / bootfs /
). The feature selection workﬂow was implemented as a bootstrapping
procedure with 100 iterations as illustrated in Fig. 1 to derive a ﬁnal
feature set. Parameters for the SCAD-SVM method were set to 1000
maximum iterations and 500 minimum evaluations. The n.threshold
parameter for the PAM classiﬁcation was set to 30, and the maxRuns
parameter for the RF-Boruta algorithm to 300. All other parameters
were set to default values (for a detailed description of the parameter
settings, refer to the documentation of the bootfs package). Abundance
and co-occurrence of selected features were visualized graphically as
network, termed the importance graph in the bootfs package. Param-
eters were set to vlabel.cex = 6, max node cex = 20, node.ﬁlter = 17,
vlabel.cex.min = 0.8, vlabel.cex.max = 4, ﬁlter = 17, ewprop = 1.4,
max edge cex = 15. 
2.4. Development of risk classiﬁcation score R2LC 
A decision rule was deﬁned for the risk classiﬁcation by setting
up a logistic regression model for classifying the histologic grade de-
pending on the protein expression levels of the selected biomarkers.
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Fig. 1. Biomarker (feature) selection workﬂow using the R-package bootfs . From 100 
bootstrapped RPPA data sets the intersection of the three individual feature sets (FS), 
computed using RF-Boruta, PAM, and SCAD-SVM, was used to generate 100 intersected 
feature sets . Counting the occurrences of each feature in the intersected feature sets 
yielded the ﬁnal ranking of the proteins according to their relevance for the classiﬁca- 
tion. RF-Boruta, random forests with the Boruta algorithm for feature selection; PAM, 
prediction analysis for microarrays; SCAD-SVM, smoothly clipped absolute deviation 
support vector machine. 
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ronsidering a binary response variable Y (i.e. histologic grade, where 
1 is coded as y = 0 and G3 as y = 1) the model is written as: 
P ( Y = 1 | X = x ) = π ( x ) 
[ R 2 LC ] = logit ( π ( x ) ) = log 
(
π ( x ) 
1 − π ( x ) 
)
= β0 + β1 x 1 + β2 x 2 + · · ·
+ βp x p + ε 
here X is an N × p -matrix of RPPA derived protein expression val- 
es, N is the number of samples, and p is the number of predictor 
ariables. β is the vector of p + 1 coefﬁcients to be estimated (in- 
luding an intercept term β0 ) and ε is the random error component 
n the model. Thus, x = [ x 1 , x 2 , . . . , x p ] is a vector of predictors for
ne sample. The training matrix is log transformed and subsequently 
tandardized by subtracting the overall median and dividing by the 
verall median absolute deviation (MAD) for each data point. From 
his standardized training matrix X the ﬁnal coefﬁcients ˆ β are esti- 
ated using maximum likelihood estimation and are subsequently 
sed for the calculation of the RPPA Risk Logistic Classiﬁcation (R2LC) 
core. To classify a new sample, we standardized the predictor protein 
ntensities for the 4 markers by subtracting the median and dividing 
y the MAD. 
.5. Western blot 
Western blotting was done as described previously [ 20 ]. In brief, 
umor lysates were prepared as described above and 20 μg total pro- 
ein of representative tumor samples were used for blotting and sub- 
equent incubation with antibodies speciﬁc for caveolin-1 (ab32577, 
bcam), NDKA (5353, Cell Signaling Technologies), and RPS6 (2217, 
ell Signaling Technologies). As a loading control, an antibody di- 
ected against β-actin (69,100, MP Biomedicals) was used. 2.6. Transcriptional proﬁling 
Total RNA was isolated from tumor samples using the miRNeasy 
Mini kit (Qiagen) according to manufacturer ’ s instructions. Quality 
control of total RNA as well as labeling and hybridization to Sentrix 
Human HT-12 v4 BeadChips (Illumina) was performed at the DKFZ 
Proteomics and Genomics Core Facility. Data were normalized using 
the quantile algorithm of the Bioconductor limma package [ 27 ]. The 
limma package was also used to compute array weights and ﬁlter out 
less reliable arrays and to compute the differentially expressed genes 
(Benjamini-Hochberg adjusted p -values < 0.05). Functional gene en- 
richment analysis was performed using DAVID Bioinformatics Re- 
sources 6.7 with default settings [ 28 ]. Enriched Gene Ontology (GO) 
terms were visualized using REVIGO [ 29 ]. 
2.7. Statistical analysis 
Statistical analysis including Wilcoxon rank sum test, Kruskal–
Wallis test, and Spearman ’ s rank correlation as well as cluster anal- 
ysis based on correlation combined with Ward ’ s linkage rule and 
illustration as heatmap was performed using R version 2.13.1 ( http: / 
/ www.R-project.org ). ROC curves were generated using the ROCR 
package [ 30 ]. 
3. Results 
3.1. Biomarker identiﬁcation process 
Cell lysates were prepared from freshly frozen tumors obtained 
from patients with hormone receptor-positive primary invasive 
breast carcinoma and analyzed by RPPA. This targeted proteome pro- 
ﬁling approach was aimed at the identiﬁcation of a robust set of pro- 
tein biomarkers to classify patients according to their risk of cancer 
recurrence. Quantitative protein expression data were obtained for 
128 different proteins and phosphoproteins. The biomarker selection 
process was based on the idea of using quantitative protein expres- 
sion data of tumor samples, classiﬁed as histologic G1 ( n = 14) and 
histologic G3 ( n = 22), as surrogates for the low and high risk group, 
respectively. To exploit the particular strengths of different methods 
we combined three classiﬁcation algorithms SCAD-SVM, RF-Boruta, 
and PAM, to a single approach, named bootfs . An overview of the 
bootfs workﬂow is depicted in Fig. 1 . Ahead of bootfs , the performance 
of each individual classiﬁcation method was assessed by 5-fold cross- 
validation and the ROC analysis resulted in area under the curve (AUC) 
values between 0.90 and 0.95 (Supplementary Fig. S1). 
The result of the bootfs biomarker selection process was visualized 
as importance graph ( Fig. 2 A). In addition, bootfs was repeated 20 
times to determine the robustness of the biomarker selection process. 
Candidate biomarker proteins were ranked according to their relative 
selection frequency and the rank variation was calculated ( Fig. 2 B). 
Caveolin-1 was selected in over 90% of the selection runs into an 
intersected feature set . The second top candidate was NDKA which 
was part of > 80% of all intersected feature sets . RPS6, identiﬁed as 
third protein, was selected in close to 50% of all selection runs. All 
other candidate biomarkers reached a selection frequency of about 
20% or lower. 
Among the top 10 hits to discriminate between histologic G1 
and G3 tumor samples were Ki-67, TOP2A, and PCNA presenting 
well known cancer-relevant proliferation markers. As expected, these 
three proteins were signiﬁcantly higher expressed in histologic G3 
samples ( Fig. 3 A). However, the three top hits for classiﬁcation of tu- 
mors either as low or high risk were caveolin-1, NDKA, and RPS6. RPPA 
data indicated that caveolin-1 was strongly expressed in histologic G1 
tumors but was downregulated in G3 tumors. Increased expression 
of NDKA and RPS6 was observed in high grade tumors ( Fig. 3 A). The 
differential expression of caveolin-1, NDKA, and RPS6 identiﬁed by 
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Fig. 2. Summary of bootfs biomarker selection result. (A) Importance graph : node size represents the frequency of a particular protein in 100 intersected feature sets . The edge width 
is proportional to co-occurrence of the nodes adjacent to the edge. (B) The bootstrapped feature selection was repeated 20 times with differing random seeds and the ranks of each 
feature across these 20 repeats are shown, sorted in decreasing order. Error bars indicate the 95% conﬁdence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RPPA was subsequently conﬁrmed by Western blot (Supplementary
Fig. S2). 
3.2. Risk classiﬁcation score R2LC 
Next we evaluated whether the top candidates of the bootfs -based
selection process, caveolin-1, NDKA, RPS6, and Ki-67 can reﬂect the
readout obtained by histologic grading. Protein expression levels were
visualized as result of a two-way hierarchical cluster analysis which
separated the 109 analyzed tumor samples in two highly uniform
groups. One group comprised G1 tumor samples whereas the other
group was characterized by samples classiﬁed as G3 ( Fig. 3 B). Inter-
estingly, G2 tumor samples did not form a distinct molecular group
but covered the full expression range of G1 and G3 samples with
respect to the selected biomarkers. 
To assign tumor samples either to the low or high risk group of
cancer relapse according to the biomarker marker proﬁle, a risk clas-
siﬁcation score named R2LC (RPPA Risk Logistic Classiﬁcation) was
developed. This score represents the predicted log odds of a sample
for being high risk (similar to G3) over being low risk (similar to G1).
The predictor matrix X is a 36 × 4-matrix of log transformed and
standardized RPPA derived protein expression values for the 36 sam-
ples (14 G1 and 22 G3) of the discovery cohort and the 4 selected
markers. β is the vector of 5 coefﬁcients to be estimated (includingan intercept term β0 ). Thus, x = [ x 1 , x 2 , x 3 , x 4 ] is a vector of predictors
for one sample. Estimation of the model coefﬁcients yielded the R2LC
score deﬁnition: 
[ R 2 LC ] = 1594 . 65 − 677 . 03 × [ c ave olin - 1 ] + 33 . 33 × [ NDK A ] 
−129 . 30 × [ RP S 6 ] + 1193 . 67 × [ K i - 67 ] 
The decision for low risk (similar to G1) and high risk (similar to
G3) is made by taking the sign of the R2LC score, i.e. negative log odds
predict low risk and positive log odds predict high risk. 
The performance of R2LC was validated on an independent test
set consisting of 39 G1 and 24 G3 tumor samples. The classiﬁcation
was done using R2LC by ﬁrst log-transforming and scaling the input
predictor variables (protein abundance of the four markers measured
by RPPA) and then plugging in the preprocessed data into the R2LC
prediction model. ROC curve analysis revealed a good performance
of the prediction with an AUC of 0.78 ( Fig. 4 ). Out of 39 G1 cases 32
were classiﬁed as low risk and out of 24 G3 cases 15 were classiﬁed
as high risk. 
Due to the limited follow-up time (median = 3 years), a detailed
analysis of recurrence-free survival has not been carried out for the
R2LC-derived risk groups. 
56 Johanna Sonntag et al. / 2 (2014) 52–59 
Fig. 3. Differential expression of selected proteins. (A) Cell proliferation markers Ki-67, 
TOP2A, and PCNA were among the top 10 hits showing signiﬁcantly higher expression 
in histologic G3 tumor samples ( p < 0.001, Wilcoxon rank sum test). The top 3 fre- 
quently selected biomarkers were caveolin-1, NDKA, and RPS6. Caveolin-1 was signif- 
icantly lower expressed in histologic G3 tumor samples whereas RPS6 and NDKA were 
signiﬁcantly higher expressed compared to G1 tumor samples ( p < 0.001, Wilcoxon 
rank sum test). (B) Heatmap illustrating a two-way hierarchical cluster analysis based 
on correlation combined with Ward ’ s linkage rule of caveolin-1, NDKA, RPS6, and Ki-67 
protein expression levels. Histologic G1 (blue) and G3 (red) tumor samples constitute 
independent clusters. Histologic G2 tumor samples (turquoise) cover the full range of 
protein expression observed for G1 and G3 tumors. 
Fig. 4. Performance of the risk classiﬁcation score R2LC. The R2LC model based on the 
weighted protein expression levels of caveolin-1, NDKA, RPS6, and Ki-67 was tested on 
500 bootstrap samples of an independent test data set ( n = 63). The average over all 
bootstrap ROC curves resulted in an AUC of 0.78. 
Fig. 5. Analysis of differentially expressed genes between G2 tumor samples classi- 
ﬁed either as R2LC low or high risk. Functional gene enrichment analysis revealed 
that signiﬁcantly enriched GO terms were part of the superclusters “cell division” and 
“response to hormone stimulus”. 3.3. R2LC low risk and R2LC high risk represent two distinct molecular 
groups 
Whole genome gene expression data of tumor samples classiﬁed 
as G2 were generated for a subset of the discovery cohort ( n = 47). 
Of these samples 20 were classiﬁed as low risk and 27 as high risk 
using the R2LC score. In total, 438 genes were identiﬁed as signiﬁ- 
cantly differentially expressed between those two groups (Wilcoxon 
rank test, multiple testing corrected p < 0.05). Functional gene en- 
richment analysis using DAVID resulted in 36 individual GO terms 
with signiﬁcant enrichment. The non-redundant GO term set was 
subsequently visualized as tree map using REVIGO and the analysis 
revealed the superclusters “cell division” and “response to hormone 
stimulus” as major difference between the R2LC low and high risk 
groups ( Fig. 5 ). 
3.4. Comparison of biomarker protein and mRNA expression levels 
To assess expression levels of the selected biomarkers caveolin-1, 
NDKA, RPS6, and Ki-67 on the transcript level, a comparison between 
mRNA and protein expression was carried out for 68 tumor samples of 
the discovery cohort limited to those tumors where mRNA data were 
available. Correlation analysis revealed that caveolin-1 mRNA and 
protein level were positively correlated ( p < 0.001) with a Spearman ’ s 
rank correlation coefﬁcient of ρ = 0.646. NDKA and Ki-67 also showed 
a signiﬁcant positive correlation ( p < 0.001) with ρ = 0.682 and ρ
= 0.402, respectively. In case of RPS6, no correlation between mRNA 
and protein expression was observed ( Fig. 6 A). 
The recently published breast cancer data set of Curtis et al. [ 2 ] 
was used to compare gene expression levels of caveolin-1, NDKA, and 
Ki-67 with intrinsic molecular subtypes assigned to those samples 
using gene expression proﬁling data. In line with RPPA derived re- 
sults, mRNA levels of caveolin-1 were signiﬁcantly higher in luminal 
A compared with luminal B samples. In addition, NDKA and Ki-67 
revealed a higher expression in luminal B samples ( Fig. 6 B). 
4. Discussion 
Breast cancer is nowadays recognized as a heterogeneous disease 
with different intrinsic molecular subtypes. The luminal subgroup, 
which comprises the majority of cases, can be further divided into 
luminal A and luminal B associated with better or worse prognoses, 
respectively. This classiﬁcation is crucial for therapy decisions as pa- 
tients of the luminal B subtype with high risk of recurrence should 
be treated with chemo-endocrine therapy whereas patients being at 
lower risk could be spared chemotherapy and its adverse side effects. 
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Fig. 6. Comparison of biomarker protein and mRNA expression levels. (A) Correla- 
tion analysis of protein and mRNA expression derived from RPPA and Illumina whole 
genome gene expression proﬁling, respectively. A signiﬁcant correlation was observed 
for caveolin-1, NDKA, and Ki-67 ( p < 0.001, Spearman ’ s rank correlation) but not for 
RPS6. (B) Association of high NDKA ( NME1 ) and Ki-67 ( MKI67 ) mRNA expression with 
tumor samples classiﬁed as luminal B as well as high caveolin-1 ( CAV1 ) mRNA expres- 
sion with luminal A tumor samples was conﬁrmed using the independent sample set 
of Curtis et al. [ 2 ]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 However, a proper deﬁnition of low and high risk luminal breast can-
cer to aid treatment decisions has so far remained a challenge. 
This study identiﬁed a protein biomarker signature consisting of
caveolin-1, NDKA, RPS6, and Ki-67 by using RPPA-based tumor pro-
ﬁling which should improve determining the recurrence risk in pa-
tients with luminal breast cancer. Biomarker selection was based on
a new bioinformatics approach, bootfs , ﬁrstly introduced here. Bioin-
formatics offers numerous methods to solve two-group classiﬁca-
tion problems in high-throughput data sets. However, no approach
clearly outperforms any other algorithm for all quality criteria at once,
namely prediction accuracy, feature selection stability, and biological
relevance [ 31 –32 ]. Therefore, bootfs combines three different clas-
siﬁcation methods in a bootstrap approach which simulates patient
variability and enhances the performance and stability of biomarker
selection. In detail, the three methods SCAD-SVM, RF-Boruta, and PAM
were used [ 24 –26 ]. Only those target proteins selected by all three
classiﬁcation algorithms in a particular bootstrap data set entered
the ﬁnal biomarker ranking which reﬂects the selection frequency of
certain biomarker proteins. Although bootfs was developed for RPPA
derived protein expression data, we anticipate that this approach will
also be useful for the other two-group classiﬁcation tasks. Therefore,
we made this method available as an open source package. 
Proteins part of our biomarker signature plays a role in diverse
biological processes. NDKA, for example, catalyzes the transphospho-
rylation of γ-phosphates from deoxynucleoside triphosphates to de-
oxynucleoside diphosphates to supply cells with nucleotides other
than ATP [ 33 ]. Besides cell proliferation, NDKA is involved in cell dif-
ferentiation, chromosomal stability, and signal transduction [ 34 –37 ].
Although NDKA had initially been described as NM23-H1 by Steeget al. in 1988 as a gene being downregulated in murine melanoma
cell lines with high metastatic potential [ 38 ], contradicting results
have since then been reported for this gene in other tumor entities.
For example, high levels of NDKA expression were linked with ag-
gressive types of prostate cancer and neuroblastoma [ 39 –40 ]. Our
results suggest that NDKA is a valuable marker also for the identiﬁ-
cation of high risk luminal breast cancer. In detail, NDKA was found
highly expressed in histologic G3 tumors as identiﬁed by RPPA and
conﬁrmed by Western blot. In addition, protein and mRNA expres-
sion of NDKA was highly correlated. Using a large, publically available
gene expression dataset [ 2 ], positive correlation between high NDKA
expression levels and the group of luminal B tumors was conﬁrmed.
Along with several other ribosomal proteins, RPS6 is part of the ri-
bosomal 40S subunit controlling protein synthesis rate and cell size
during cell division and differentiation [ 41 ]. RPPA-based tumor pro-
ﬁling identiﬁed RPS6 as being highly expressed in histologic G3 tumor
samples. However, RPS6 protein expression was not correlated with
transcript levels for RPS6 in line with a previous report [ 16 ] indicating
a regulation of RPS6 at the posttranscriptional level. In contrast to Ki-
67, NDKA, and RPS6, caveolin-1 was strongly expressed in histologic
G1 tumor samples and a positive correlation between protein and
mRNA levels was observed. The differential expression of caveolin-1
in luminal A and luminal B tumors was also seen in the Curtis data
set [ 2 ]. Caveolin-1 is the main component of caveolae, a subset of
lipid rafts which, for example, serve as molecular hubs modulating
the activity of signaling pathways. In the context of breast cancer,
loss of caveolin-1 in cancer-associated ﬁbroblasts results in an acti-
vated tumor microenvironment and has been linked to poor clinical
outcome [ 42 –44 ]. This is in line with our data showing that loss of
caveolin-1 expression was observed for higher grade tumors. In addi-
tion, a recent report describing a novel protein expression deﬁned a
breast cancer subgroup which was mainly characterized by stromal /
microenvironmental components. This subgroup termed “reactive I”
consisted primarily of a subset of luminal A tumors as deﬁned by
mRNA proﬁling with high caveolin-1 expression as the major feature
[ 3 ]. 
Hierarchical clustering of expression levels of the four bootfs -
selected proteins indicated that histologic G2 tumors do not form
a separate group but rather display molecular features of histologic
G1-like or G3-like samples as was previously also reported from gene
expression proﬁling studies of human breast cancer [ 45 –46 ]. In or-
der to assign individual tumor samples either to the low or high risk
group of cancer relapse according to the biomarker marker proﬁle,
a risk classiﬁcation score named R2LC was developed. The perfor-
mance of R2LC was successfully validated on an independent set of
hormone receptor-positive tumors. Furthermore, analysis of differen-
tially expressed genes of tumor samples with intermediate histologic
grade revealed that R2LC was indeed able to separate this group into
two distinct molecular entities. Differentially expressed genes were
mainly involved in processes like cell division and response to hor-
mone stimuli. In addition, it will be necessary to test the performance
of the R2LC risk classiﬁcation score on a tumor sample set with appro-
priate disease-free survival information to evaluate R2LC for correct
reclassiﬁcation of histologic G2 tumor samples into low and high risk
groups of cancer recurrence. 
Regulation of cell proliferation presents also the common driving
force behind prognostic information provided by different gene ex-
pression signatures as reviewed by Ignatiadis and Sotiriou [ 47 ]. The
St Gallen international expert consensus on the primary therapy of
early breast cancer 2011 has acknowledged such ﬁndings by suggest-
ing the use of Ki-67 staining besides histologic grading as convenient
approximation for risk classiﬁcation in early stage luminal breast can-
cer [ 48 ]. However, a recent study points out that Ki-67 quantiﬁcation
suffers from high inter- and intra-observer variabilities impeding the
risk assessment especially for moderately differentiated breast car-
cinomas [ 49 ], further underlining the need to identify a robust and
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juantitative biomarker signature. 
Immunohistochemistry is routinely used in breast cancer to de- 
ermine estrogen and progesterone receptor status as well as HER2 
eceptor status. Obtaining information on HER2 expression in addi- 
ion to assessing hormone receptor status presents a widely accepted 
asis for therapeutic decisions [ 50 –51 ]. However, little progress was 
ade in recent years to translate newly identiﬁed biomarkers into 
mmunohistochemistry-based scores that would be suitable for rou- 
ine clinical application. Major reasons are seen in technical limi- 
ations such as a high potential for a subjective interpretation of 
HC images thus complicating the deﬁnition of clear-cut quantiﬁ- 
ation guidelines [ 52 ]. This issue has so far restricted approving 
ew IHC biomarkers which is especially challenging for those pro- 
eins revealing heterogeneous subcellular staining patterns. RPPA, on 
he other hand, provides an unbiased quantitative readout to assess 
he biomarkers of interest over a large dynamic range also in non- 
issected clinical specimens [ 16 ] and has therefore a high potential 
o amend the toolbox of useful protein quantiﬁcation assays. As a ma- 
or advantage of RPPA, only small amounts of material are required 
o that this approach also presents a practical screening platform for 
he identiﬁcation of biomarker signatures. 
In conclusion, the proposed biomarker signature consisting of 
aveolin-1, NDKA, RPS6, and Ki-67 has a high potential to facilitate the 
ssessment of recurrence risk in patients with luminal breast cancer 
nd can potentially contribute to resolving the clinically challenging 
roup of luminal breast cancers that were diagnosed with interme- 
iate histologic grade. In addition, RPPA present a promising exper- 
mental platform for biomarker discovery and biomarker validation 
nd promise to deliver a platform for future biomarker quantiﬁcation 
pplications in the daily clinical routine. 
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